374 related articles for article (PubMed ID: 31948289)
41. l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.
Koeth RA; Lam-Galvez BR; Kirsop J; Wang Z; Levison BS; Gu X; Copeland MF; Bartlett D; Cody DB; Dai HJ; Culley MK; Li XS; Fu X; Wu Y; Li L; DiDonato JA; Tang WHW; Garcia-Garcia JC; Hazen SL
J Clin Invest; 2019 Jan; 129(1):373-387. PubMed ID: 30530985
[TBL] [Abstract][Full Text] [Related]
42. Dietary Methionine Restriction Alleviates Choline-Induced Tri-Methylamine-N-Oxide (TMAO) Elevation by Manipulating Gut Microbiota in Mice.
Lu M; Yang Y; Xu Y; Wang X; Li B; Le G; Xie Y
Nutrients; 2023 Jan; 15(1):. PubMed ID: 36615863
[TBL] [Abstract][Full Text] [Related]
43. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions.
Zhang LS; Davies SS
Genome Med; 2016 Apr; 8(1):46. PubMed ID: 27102537
[TBL] [Abstract][Full Text] [Related]
44. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide.
Romano KA; Vivas EI; Amador-Noguez D; Rey FE
mBio; 2015 Mar; 6(2):e02481. PubMed ID: 25784704
[TBL] [Abstract][Full Text] [Related]
45. Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis.
Yeh CF; Chen YH; Liu SF; Kao HL; Wu MS; Yang KC; Wu WK
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227973
[TBL] [Abstract][Full Text] [Related]
46. Microbial metabolites in non-alcoholic fatty liver disease.
Zhou D; Fan JG
World J Gastroenterol; 2019 May; 25(17):2019-2028. PubMed ID: 31114130
[TBL] [Abstract][Full Text] [Related]
47. Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD).
Hemmati M; Kashanipoor S; Mazaheri P; Alibabaei F; Babaeizad A; Asli S; Mohammadi S; Gorgin AH; Ghods K; Yousefi B; Eslami M
Life Sci; 2023 Sep; 329():121947. PubMed ID: 37463653
[TBL] [Abstract][Full Text] [Related]
48. Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis.
Portincasa P; Bonfrate L; Vacca M; De Angelis M; Farella I; Lanza E; Khalil M; Wang DQ; Sperandio M; Di Ciaula A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163038
[TBL] [Abstract][Full Text] [Related]
49. Targeting gut microbiota in aging-related cardiovascular dysfunction: focus on the mechanisms.
Liu S; He Y; Zhang Y; Zhang Z; Huang K; Deng L; Liao B; Zhong Y; Feng J
Gut Microbes; 2023 Dec; 15(2):2290331. PubMed ID: 38073096
[TBL] [Abstract][Full Text] [Related]
50. Gut microbiome production of short-chain fatty acids and obesity in children.
Murugesan S; Nirmalkar K; Hoyo-Vadillo C; García-Espitia M; Ramírez-Sánchez D; García-Mena J
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):621-625. PubMed ID: 29196878
[TBL] [Abstract][Full Text] [Related]
51. Role of microbiota-derived short-chain fatty acids in nervous system disorders.
Mirzaei R; Bouzari B; Hosseini-Fard SR; Mazaheri M; Ahmadyousefi Y; Abdi M; Jalalifar S; Karimitabar Z; Teimoori A; Keyvani H; Zamani F; Yousefimashouf R; Karampoor S
Biomed Pharmacother; 2021 Jul; 139():111661. PubMed ID: 34243604
[TBL] [Abstract][Full Text] [Related]
52. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
Chen ML; Yi L; Zhang Y; Zhou X; Ran L; Yang J; Zhu JD; Zhang QY; Mi MT
mBio; 2016 Apr; 7(2):e02210-15. PubMed ID: 27048804
[TBL] [Abstract][Full Text] [Related]
53. The human gut microbiota and its interactive connections to diet.
Milani C; Ferrario C; Turroni F; Duranti S; Mangifesta M; van Sinderen D; Ventura M
J Hum Nutr Diet; 2016 Oct; 29(5):539-46. PubMed ID: 27161433
[TBL] [Abstract][Full Text] [Related]
54. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
Chu H; Duan Y; Yang L; Schnabl B
Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
[TBL] [Abstract][Full Text] [Related]
55. Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.
Gupta N; Buffa JA; Roberts AB; Sangwan N; Skye SM; Li L; Ho KJ; Varga J; DiDonato JA; Tang WHW; Hazen SL
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1239-1255. PubMed ID: 32212854
[TBL] [Abstract][Full Text] [Related]
56. Role of microbiota and microbiota-derived short-chain fatty acids in PDAC.
Temel HY; Kaymak Ö; Kaplan S; Bahcivanci B; Gkoutos GV; Acharjee A
Cancer Med; 2023 Mar; 12(5):5661-5675. PubMed ID: 36205023
[TBL] [Abstract][Full Text] [Related]
57. Dietary factors, gut microbiota, and serum trimethylamine-N-oxide associated with cardiovascular disease in the Hispanic Community Health Study/Study of Latinos.
Mei Z; Chen GC; Wang Z; Usyk M; Yu B; Baeza YV; Humphrey G; Benitez RS; Li J; Williams-Nguyen JS; Daviglus ML; Hou L; Cai J; Zheng Y; Knight R; Burk RD; Boerwinkle E; Kaplan RC; Qi Q
Am J Clin Nutr; 2021 Jun; 113(6):1503-1514. PubMed ID: 33709132
[TBL] [Abstract][Full Text] [Related]
58. The Gut-Liver Axis in Health and Disease: The Role of Gut Microbiota-Derived Signals in Liver Injury and Regeneration.
Zheng Z; Wang B
Front Immunol; 2021; 12():775526. PubMed ID: 34956204
[TBL] [Abstract][Full Text] [Related]
59. Short chain fatty acids in human gut and metabolic health.
Blaak EE; Canfora EE; Theis S; Frost G; Groen AK; Mithieux G; Nauta A; Scott K; Stahl B; van Harsselaar J; van Tol R; Vaughan EE; Verbeke K
Benef Microbes; 2020 Sep; 11(5):411-455. PubMed ID: 32865024
[TBL] [Abstract][Full Text] [Related]
60. Gut Microbiome and AKI: Roles of the Immune System and Short-Chain Fatty Acids.
Gharaie S; Noel S; Rabb H
Nephron; 2020; 144(12):662-664. PubMed ID: 32721962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
